Congleton Jon 4

What Happened Jon Congleton, CEO of Mineralys Therapeutics (MLYS), received awards on February 19, 2026 totaling 328,800 shares: 140,900 restricted stock units (RSUs) and 187,900 derivative awards. Both grants were reported at $0.00 per share (no cash paid at grant). The RSUs and the derivative award are compensation grants subject to vesting schedules described in the filing.

Key Details

• Transaction date: 2026-02-19; Form 4 filed: 2026-02-20.
• Grants: 140,900 RSUs @ $0.00 (footnote F1) and 187,900 derivative award @ $0.00 (footnote F2).
• Vesting: RSUs vest annually over four years (1/4 each year); the derivative award vests monthly over four years (1/48 each month).
• Transaction code: A (award/grant).
• Shares owned after transaction: Not specified in the provided excerpt of the Form 4.
• Filing timeliness: Reported the next day; no late filing indicated.

Context RSUs are a promise to deliver shares upon vesting; the derivative award appears to be an equity-based grant (per the footnote) with monthly vesting and will only convert to usable shares if and as it vests or is exercised per plan terms. Awards are common executive compensation and do not necessarily signal immediate buying or selling intent—these grants increase potential future share exposure but cannot be sold until vesting and any applicable exercise/settlement and tax requirements are met.